SCHEMBL4955640

SCHEMBL4955640

O=CCn1cnc(-c2ccccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2A6 P11509 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2B6 P20813 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2D6 P10635 1/20 0.50
HPGDS O60760 1/20 0.48
PDE10A Q9Y233 1/20 0.45
TBXA2R P21731 1/20 0.44
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
NLRP3 Q96P20 1/20 0.41
FAAH O00519 1/20 0.39
KDM4C Q9H3R0 2/20 0.39
KDM4A O75164 1/20 0.39
LMNA P02545 1/20 0.38
PRNP P04156 1/20 0.38
MAPT P10636 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5718131 0.83 PDE10A (0.49) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL1539107 0.83 HPGDS (0.48) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL8655249 0.83 HPGDS (0.48) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL2910946 0.78 CYP2E1 (0.67) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL13978068 0.77 HPGDS (0.55) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL9810711 0.77 HPGDS (0.51) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL11387286 0.76 PTGS2 (0.37) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL5717716 0.76 CYP2E1 (0.50) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL1346083 0.75 HPGDS (0.77) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL7990801 0.74 CYP2E1 (0.53) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791843-B1 MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-08-29 EP disclosed
EP-1606264-B1 MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-05-02 EP disclosed
US-7659300-B2 Monocyclic anilide spirolactam CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2010-02-09 US disclosed
US-7659300-B2 Monocyclic anilide spirolactam CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2010-02-09 US disclosed
US-20090054408-A1 Monocyclic anilide spirolactam cgrp receptor antagonists MERCK SHARP & DOHME LLC 2009-02-26 US disclosed
US-20090054408-A1 Monocyclic anilide spirolactam cgrp receptor antagonists MERCK SHARP & DOHME LLC 2009-02-26 US disclosed
US-7192954-B2 Monocyclic anilide spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-03-20 US disclosed
US-7192954-B2 Monocyclic anilide spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054408-A1 Monocyclic anilide spirolactam cgrp receptor antagonists BDKRB1, BDKRB2, CALCRL CYP2E1 3203/4885CYP3A4 3589/4885CYP2A6 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.